AKR1C3 and neoplasm: Previous studies show that AKR1C3 has been upregulated in abiratarone resistant tumors [32, 33], suggesting that, in the AR responsive phase, androgen biosynthesis is inhibited but that, in resistance phase, tumor cells acquire the capacity to overexpress AKR1C3 enzyme.